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flaviviral envelope domain III: induction of Dengue
and West Nile virus neutralizing antibodies
Anthony JS Chua1,2, Cyrielle Vituret3,4, Melvin LC Tan1, Gaëlle Gonzalez3,4, Pierre Boulanger3, Mah-Lee Ng1,2,5*
and Saw-See Hong3,4,6*Abstract
CD16-RIgE is a chimeric human membrane glycoprotein consisting of the CD16 ectodomain fused to the
transmembrane domain and cytoplasmic tail of the gamma chain of the high affinity receptor of IgE (RIgE).
Coexpression of CD16-RIgE and HIV-1 Pr55Gag polyprotein precursor (Pr55GagHIV) in insect cells resulted in the
incorporation of CD16-RIgE glycoprotein into the envelope of extracellular virus-like particles (VLPs), a phenomenon
known as pseudotyping. Taking advantage of this property, we replaced the CD16 ectodomain of CD16-RIgE by the
envelope glycoprotein domain III (DIII) of dengue virus serotype 1 (DENV1) or West Nile virus Kunjin (WNVKun). The
two resulting chimeric proteins, DIII-DENV1-RIgE and DIII-WNVKun-RIgE, were addressed to the plasma membrane,
exposed at the surface of human and insect cells, and incorporated into extracellular VLPs when coexpressed with
Pr55GagHIV in insect cells. The DIII domains were accessible at the surface of retroviral VLPs, as shown by their
reactivity with specific antibodies, and notably antibodies from patient sera. The DIII-RIgE proteins were found to be
incorporated in VLPs made of SIV, MLV, or chimeric MLV-HIV Gag precursors, indicating that DIII-RIgE could pseudotype
a wide variety of retroviral VLPs. VLP-displayed DIII were capable of inducing specific neutralizing antibodies against
DENV and WNV in mice. Although the neutralization response was modest, our data confirmed the capability of DIII to
induce a flavivirus neutralization response, and suggested that our VLP-displayed CD16-RIgE-based platform could be
developed as a vaccine vector against different flaviviruses and other viral pathogens.
Keywords: Flavivirus envelope glycoprotein, Domain III, Retroviral Gag, Virus-like particles (VLPs), Pseudotyping,
VLP-display, CD16/FcεRIγ chimera, Recombinant baculovirusIntroduction
Flaviviruses like dengue virus (DENV) and West Nile
virus (WNV) have established strongholds in many parts
of tropical and sub-tropical countries world-wide. They
are among the most important agents of re-emerging dis-
eases. These viruses are transmitted by mosquito vectors
and with global warming, the potential territorial expansion
for the spread of these diseases are real. According to WHO
(http://www.who.int/mediacentre/factsheets/fs117/en/),
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reproduction in any medium, provided the oreach year. To date, there is still no efficient vaccine nor
antiviral for human use for either virus. Efficient vaccines
are those inducing a robust neutralizing immune re-
sponse, and the presentation of epitopes inducing virus
neutralization activity (NA) is obviously optimal in whole
virus vaccines, and in virus-like particles (VLPs) which
mimic natural virions [1]. This is best illustrated by the
VLP-based strategy against human papilloma virus (HPV),
recently approved for human vaccination against HPV in-
fections and HPV-associated cervical lesions cancerous in
nature [2,3].
VLPs are highly organized particulate structures, which
differ in nature and composition from infectious virions,
most importantly by lacking the viral genome. VLPs can
be made up solely of viral capsid proteins such as in the
case of HPV, as mentioned above, and hepatitis E virustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phage AP205 [5]. VLPs consisting only of viral envelope
glycoproteins have been isolated, such as the subviral par-
ticles formed by hepatitis B virus (HBV) envelope glyco-
protein S, or by chimeric HBV and hepatitis C virus
(HCV) envelope proteins [6,7]. In the case of the influenza
virus, VLPs produced by recombinant baculovirus-infected
insect cells consisted of two membrane-associated proteins,
hemagglutinin and matrix protein [8].
VLPs based on retroviruses or lentiviruses, e.g. human
immunodeficiency virus (HIV), represent another type
of subviral structure. They are membrane-enveloped par-
ticles made up of a backbone of viral polyprotein Gag (or
Gag precursor; Pr), wrapped by an envelope derived from
the host cell plasma membrane. The HIV-1 Gag precursor
(Pr55Gag) spontaneously assembles into VLPs, which bud
at the plasma membrane of Gag-expressing insect cells,
and are structurally similar to immature virions except
that they do not contain any viral genetic material [9-15].
During their budding process, the membrane-enveloped
viruses and VLPs bring with them glycoproteins of both
viral and nonviral origins present in the plasma membrane
of producer cells [16]. Substitution of the viral envelope
gene by another type of envelope glycoprotein is a phe-
nomenon which is referred to as pseudotyping. Pseudo-
typing has been described for various enveloped viruses,
including retroviruses, lentiviruses, vesicular stomatitis
virus (VSV), HCV and baculoviruses [17-22].
The non-replicative nature of VLPs and their struc-
tural analogy to natural viruses make them highly at-
tractive candidates for the design of subunit vaccines
which carry the immunogenic structures of the virus in
the absence of infectious genetic material. In addition,
VLPs can induce both humoral and cellular mediated
immune responses [23]. Considering that mosquitos are
intermediate hosts for DENV and WNV, the use of the
baculovirus-insect cell expression system for the produc-
tion of VLPs pseudotyped by the envelope glycoprotein
(E) of DENV and WNV, or by E-derived structural do-
mains, represents a logical approach for the develop-
ment of VLP-based vaccines against these flaviviruses.
The E domain III (DIII) was chosen as our candidate
subunit vaccine in view of several reasons. DIII is the
putative receptor binding domain in flaviviruses. Anti-
bodies that bind specifically to DIII have been shown to
be highly efficient in preventing virus adsorption to cells
[24,25]. DIII contains numerous neutralizing epitopes
to which binding of specific antibodies can effectively
lead to neutralization of the virus. In addition to several
other groups, we have also demonstrated that DIII is
highly immunogenic. When used as subunit vaccines,
DIII is able to induce protective immune responses
against flaviviruses in both rodents and non-human pri-
mates [26-37].CD16-RIgE is a chimeric receptor molecule consisting
of the ectodomain of CD16 fused to the transmembrane
and cytoplasmic domains of FcεRIγ (abbreviated RIgE in
the present study), the gamma polypeptide chain of the
high affinity IgE-Fc receptor [38]. Human CD16 (or
FcγRIIIa) is one of the low-affinity receptors for IgG Fc
and is involved in antibody-dependent cell-mediated
cytotoxicity (ADCC). It allows the recognition of IgG-
sensitized target cells by CD16-bearing cytotoxic cells (i.e.
CD56dim natural killer cells [39], a fraction of monocytes,
macrophages and rare T cells), and the activation of these
effector cells [38]. When expressed in human cells, the
CD16-RIgE glycoprotein is trafficked to the cell surface
via the Golgi pathway [38].
In the present study, we designed a strategy of pseudo-
typing retrovirus-based VLPs consisting of the co-
expression of a retroviral Gag polyprotein, forming the
VLP scaffold, and CD16-RIgE in insect cells. The
polyprotein Pr55GagHIV in HIV-1-infected human cells is
addressed to the late endosomal compartment and plasma
membrane, via its N-myristoyl group and a cluster of basic
residues located in the matrix domain [9,16,40]. In Sf9 in-
sect cells, the recombinant Pr55GagHIV is also addressed
to the plasma membrane, and efficiently self-assembles
into VLPs, which bud and egress from the cell surface
[10,13-15,41]. CD16-RIgE was found to be efficiently in-
corporated into the envelope of extracellular VLPs, and
served as the pseudotyping platform. We showed that sub-
stitution of the CD16 ectodomain by the DIII domain
from DENV or WNV E glycoprotein resulted in a
chimeric flaviviral/human fusion protein DIII-RIgE, which
was incorporated into extracellular VLPs. The DIII do-
main was exposed at the surface of the VLP envelope, and
VLP-displayed DIII epitope(s) induced DENV and WNV
neutralizing antibodies in mice. These results suggested
that our VLP-displayed CD16-RIgE-based platform could
be applied to the generation of recombinant vaccines
against various viral and microbial pathogens.
Materials and methods
Cells and viruses
(i) Insect cells. Spodoptera frugiperda Sf9 cells were
maintained as monolayers at 28°C in Grace’s insect
medium supplemented with 10% fetal bovine serum (FBS)
and antibiotics (Invitrogen). They were infected with re-
combinant baculovirus at a multiplicity of infection (MOI)
ranging from 5 to 10 PFU/cell, as previously described
[11,13,14,41-45]. In co-expression experiments, Sf9 cells
were infected with two recombinant baculoviruses simul-
taneously at equal MOI [45-47]. (ii) Mammalian cells.
Human embryonic kidney HEK293 cells were obtained from
the American Type Culture Collection (ATCC; Manassas,
VA), and maintained as monolayers in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) supplemented with 10%
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at 37°C and 5% CO2. Baby hamster kidney BHK21 cells
used for plaque assays were maintained in conditions simi-
lar to HEK293 cells, in Roswell Park Memorial Institute-
1640 medium (RPMI-1640; Sigma-Aldrich). (iii) Viruses.
The Dengue serotype 1 virus used throughout this work was
a laboratory-adapted clinical strain isolated in Singapore. It
was a kind gift from the Environmental Health Institute
(EHI), Singapore. The WNV Kunjin strain (WNVKun)
belongs to the MRM 61C strain, a kind gift from the late
Professor E.G. Westaway, Monash University, Australia
[48]. Both viruses were propagated in Aedes albopictus
mosquito C6/36 cell line in Leibovitz-15 medium (L-15;
Sigma-Aldrich) supplemented with 10% heat-inactivated
FBS at 28°C.
Recombinant baculoviruses
All foreign genes were inserted into the genome of
Autographa californica MultiCapsid NucleoPolyhedrosis
Virus (AcMNPV) under the control of a chimeric
AcMNPV-GmNPV polyhedrin promoter, as described in
previous studies [12-14,41,44,46,49]. AcMNPV-Pr55GagHIV
expressed the N-myristoylated, full-length Gag polyprotein
(Pr55GagHIV) of HIV-1 [12-14]. AcMNPV-Pr57GagSIV,
AcMNPV-Pr65GagMLV and AcMNPV-Pr72GagMLV-HIV have
been described in a previous study [44].
VLP production and isolation
Culture supernatants of baculovirus-infected, Gag-
expressing Sf9 cells were clarified by low-speed centrifuga-
tion. VLPs were then recovered using a two-step procedure
comprising 20% sucrose cushion ultracentrifugation, fol-
lowed by ultracentrifugation in linear sucrose-D2O gradi-
ent [44,47,49]. In brief, (a) VLPs were first recovered by
pelleting through a cushion of 20% sucrose in TNE buffer
(TNE: 100 mM NaCl, 10 mM Tris–HCl pH 7.4, 1 mM
Na2EDTA) at 30,000 rpm for 1 h at 15°C in a Kontron
TST-55.5 rotor. VLP pellets from step (a) were gently
resuspended in PBS (0.20-0.25 mL), and (b) further puri-
fied by isopycnic ultracentrifugation in sucrose-D2O gradi-
ents. Linear gradients (10-mL total volume, 30-50% w:v)
were centrifuged for 18 h at 28,000 rpm in a Beckman
SW41 rotor. The 50% sucrose solution was made in D2O
buffered to pH 7.2 with NaOH, and the 30% sucrose solu-
tion was made in 10 mM Tris–HCl, pH 7.2, 150 mM
NaCl and 5.7 mM Na2EDTA. Aliquots of 0.4 mL were col-
lected from the top, and proteins analysed by SDS-PAGE
and immunoblotting. Protein concentration in samples
was determined by Bradford protein assay (Thermo Fisher
Scientific Inc.).
Determination of VLP titers
Cryoelectron microscopy and scanning electron micros-
copy have shown that one immature HIV-1 particle (thestructural equivalent of VLPs; [15]) contains approxi-
mately 5,000 copies of closely packed Pr55Gag protein
[50-52]. The HIV-1 mature capsid is a fullerene-like con-
ical structure composed of approximately 250 hexamers
and 12 pentamers of the viral CAp24 protein [53], gene-
rated by proteolytic cleavage of Pr55Gag molecules. The
fullerene core accounts for 1,560 copies of CAp24 per
core, a theoretical number which is consistent with the
value of 1,500 copies of CAp24 protein per mature core,
determined by biochemical methods [52,54]. This implied
that less than half of the Pr55Gag molecules are used to
form mature cores made of CAp24 proteins [50-52]. The
protein concentration in VLPs was estimated by SDS-
PAGE analysis of VLP samples, by comparing the intensity
of the Pr55Gag signal after Coomassie blue staining with
a range of bovine serum albumin (BSA) samples of
known concentrations co-electrophoresed in the same
gel. Taking into account the value of 5,000 Pr55Gag copies
per VLP, we calculated that a concentration of 1 mg/mL
of Pr55Gag protein corresponded to a titer of ~ 2 × 1012
VLPs per mL.
Construction of AcMNPV expressing chimeric human
glycoprotein CD16-RIgE
The plasmid pcDNA3.1/FcγRIIIa/FcεRIγ, expressing the
chimeric human construct abbreviated CD16-RIgE in the
present study was obtained from Henri Vié and Béatrice
Clémenceau (INSERM U-609, Nantes; [38]). CD16-RIgE
consisted of the fusion of the ectodomain of FcγRIIIa
(or CD16), the human low-affinity receptor for IgG Fc
(involved in antibody-dependent cell-mediated cytoto-
xicity; ADCC), to the transmembrane and cytoplasmic do-
mains of the gamma polypeptide of the human high
affinity receptor for IgE, FcεRIγ. In terms of functionality,
the CD16 ectodomain was responsible for the recognition
of IgG Fc, whereas FcεRIγ transduced the intracellular sig-
nals [38]. The cDNA encoding CD16-RIgE was rescued
using conventional overlapping PCR, and inserted into the
NheI and HindIII sites of the pBlueBac4.5 vector genome
(Invitrogen). Recombinant AcMNPV-CD16-RIgE were
isolated using beta-galactosidase staining of positive Sf9
cells and blue plaque selection.
Construction of recombinant AcMNPV expressing
flaviviral/human chimeric protein DIII-RIgE
The DIII domains of Dengue virus serotype 1 (DENV1)
and West Nile Virus Kunjin (WNVKun) have been cloned
into the pET28a vector (Novagen), and expressed in bac-
terial cells [28,29,31,55,56]. Both clones contained an
oligo-histidine sequence (His6-tag) at their N-termini. The
CD16 ectodomain was deleted from the pcDNA3.1/
CD16-RIgE vector, by double cleavage at the Bgl II and
EcoR I sites, and substituted with the cDNA fragment of
His6-tagged DIII domain from the two flavivirus selected
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were abbreviated pcDNA3.1-DIII-DENV1-RIgE and
pcDNA3.1-DIII-WNVKun-RIgE. Each construct encoded,
from the N- to C-terminus, the CD16 signal peptide,
His6-tag, DIII domain, and RIgE C-terminal transmem-
brane and cytoplasmic moieties, as depicted in Figure 1.
Each construct was then reinserted into the pBlueBac4.5
vector genome, to generate two recombinant baculoviruses
AcMNPV-DENV1-RIgE and AcMNPV-WNVKun-RIgE.
Gel electrophoresis, membrane transfer and antibodies
Polyacrylamide gel electrophoresis of SDS-denatured
protein samples (SDS-PAGE), and immunoblot analysis
have been described in detail in previous studies [44,
47,49]. Briefly, samples were denatured in SDS/beta-
mercaptoethanol-containing loading buffer at 100°C for
2 min, and proteins electrophoresed in SDS-denaturing
10% polyacrylamide gel and electrically transferred to
nitrocellulose membrane (Hybond™-C-extra; GE Health-
care Life Sciences). Blots were blocked in 5% skimmed
milk in Tris-buffered saline (TBS) containing 0.05%
Tween-20 (TBS-T), rinsed in TBS-T, then successively in-
cubated with primary antibody and phosphatase- or
peroxidase-labeled secondary antibodies. Mouse monoclo-
nal anti-His6 tag antibody was purchased from ClontechMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVL
SYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLL
GKGRKYFHHNSDFYIPKATLKDSGSYFCRGLVGSKNVS
AILFLYGIVLTLLYCRLKIQVRKAAITSYEKSDGVYTG
(A) CD16-RIgE sequence
(B) DIII-RIgE chimera : strategy of construc
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Figure 1 VLP-display of flavivirus antigenic DIII domain. (A), Amino aci
chimeric molecule composed of the extracellular domain of CD16, and transm
the human high affinity IgE receptor (FcεRIg), abbreviated RIgE in the present
sequence are the following: italics, signal peptide (aa residues 1-22); standard
transmembrane domain (aa 210-231); underlined with solid line, cytoplasmic
ectodomain, replaced by the flavivirus envelope DIII domain. (B), Strategy of c
co-expression with HIV-1 Pr55Gag in Sf9 cells doubly infected with baculoviruLaboratories Inc. (6xHis monoclonal antibody), and anti-
human CD16 mouse monoclonal antibody DJ130C from
Santa Cruz Biotechnology. Anti-HIV-1 Gag rabbit poly-
clonal antibody (laboratory-made; [44]) was raised in
rabbit by injection of the band of Pr55Gag protein
extracted from SDS-gel. The anti-Pr55GagHIV serum was
found to efficiently react with Pr57GagSIV [44]. Rabbit
polyclonal antibody to MLV-GagCAp30 protein was
purchased from antibodies-online Inc. When necessary,
proteins were detected on blots by reaction with
peroxidase-labeled antibody and SuperSignalW West Pico
chemiluminescence substrate (Thermo Fisher Scientific
Inc.). Luminograms were visualized using the Fusion X7
imaging system with the Bio1D software (Vuilbert-
Lourmat, Marne-la-Vallée, France). Apparent molecular
weights were estimated by comparison with prestained
protein markers (Precison Plus Protein™ Standards, Dual
Color; Bio-Rad Laboratories, Inc.).
ELISA
The accessibilty of recombinant DIII proteins at the sur-
face of VLPs was evaluated by their reactivity with specific
anti-flavivirus antibodies in standard ELISA procedure. In
brief, aliquots (100 μL) of VLP suspension (50 μg/mL;
1011 VLPs/mL) in coating buffer (0.1 M NaHCO3, pH 9.6)EKDSVTLKCQGAYSPEDNSTQWFHNESHISSQAS
LQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQN
SETVNITITQGLAVSTISSFFPPGEFPQLCYILD
LSTRNQETYETLKHEKPPQ-273 
tion and VLP-display  
DIII    
VLP 
Pr55Gag
gE
 domain  
His-Tag 
d sequence of the CD16-RIgE cloning platform. The CD16-RIgE is a
embrane (TM) domain and cytoplasmic tail (CT) of the gamma chain of
study. Symbols for the different domains of the amino acid (aa)
capitals, ectodomain of CD16 (aa 23-209); underlined with dotted line,
domain (aa 232-273); shaded residues, deletion (aa 23-206) of the CD16
onstruction of the DIII-RIgE chimera (left), and of VLP-display (right), by
s recombinants AcMPV-DIII-RIgE and AcMNPV-Pr55GagHIV.
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plates (NUNC). The plates were blocked at 37°C for
30 min using serum diluent made up of PBS with 0.1%
Tween 20 (PBS-T) and 5% skimmed milk. For DIII-DENV1,
patients sera positive for DENV infection, used under eth-
ical approval, was diluted 100 times with serum diluent.
For DIII-WNVKun, two antibodies were used: mouse
monoclonal antibody 3.67G, raised against the Kunjin en-
velope protein (Chemicon International, Inc.), recognizing
a DIII epitope [57]; anti-WNV-DIII rabbit polyclonal anti-
body, a kind gift from S. Lecollinet, Ecole Nationale
Vétérinaire d’Alfort, Maisons-Alfort, France [58]. Reagents
were added to wells in the following order: diluted human
antisera or primary animal antibodies, diluted (1:250) sec-
ondary anti-human, anti-rabbit or anti-mouse IgG-biotin
conjugate (Chemicon International, Inc.), diluted (1:5,000)
streptavidin-HRP conjugate (Chemicon International,
Inc.), TMB One substrate solution (Promega Corpor-
ation), and 0.5 M sulfuric acid stop-solution. All wells
were washed with PBS-T thrice before the addition of
each reagent, except before the stop solution was added.
Plates were also incubated for 1 h at 37°C after the
addition of each reagent. Absorbance was finally measured
at 450 nm.
Immunofluorescence (IF) microscopy
Baculovirus-infected Sf9 cell monolayers were harvested
at 48 h post infection (hpi), fixed with 3% paraformalde-
hyde in phosphate buffered saline (PBS) and, when re-
quired, permeabilized with 0.2% Triton X-100 in PBS.
Cells were blocked with 3% BSA in PBS (PBS-BSA), and
His-tagged DIII detected at the surface of non-
permeabilized cells by reaction with monoclonal anti-
His6 tag antibody (1:1,000 in PBS-BSA) and Alexa
FluorW 488-labeled goat anti-mouse IgG antibody (Life
Technologies Corp.). For double labeling of DIII and
Gag proteins, Sf9 cells were permeabilized and reacted
with rabbit anti-Gag antibody (1:1,000 in PBS-BSA) and
Alexa FluorW 594-labeled goat anti-rabbit IgG (Life
Technologies Corp.). HEK293 cell samples were labeled
using Image-iT™ LIVE Plasma Membrane and Nuclear
Labeling Kit (Invitrogen), which provides red-fluorescent
Alexa FluorW 594 wheat germ agglutinin (WGA) and
blue-fluorescent Hoechst-33342 dye for plasma mem-
brane and nucleus staining, respectively. For confocal
microscopy, samples were analyzed using a Nikon A1R
fast laser scanning confocal microscope.
Electron microscopy (EM) and immuno-EM
VLP specimens were processed and observed under EM
as previously described [17]. In brief, VLPs were diluted
in 20 μL 0.14 M NaCl, 0.05 M Tris–HCl buffer, pH 8.2
(Tris-buffered saline; TBS) and adsorbed onto carbon-
coated formvar membrane on grids. The grids wereincubated with primary antibody (monoclonal anti-His6
tag antibody) at a dilution of 1:50 in TBS for 1 h at room
temperature (RT). After rinsing with TBS, the grids were
post-incubated with 10-nm colloidal gold-tagged goat
anti-mouse IgG antibody (British Biocell International
Ltd, UK; diluted to 1:50 in TBS) for 30 min at RT. After
rinsing with TBS, the specimens were negatively stained
with 1% sodium phosphotungstate in H2O for 1 min at
RT, rinsed again with TBS, and examined under a JEM
1400 JEOL electron microscope equiped with an Orius-
Gatan digitalised camera (Gatan, France).
Mice immunization
The immunization regime was inspired from the proto-
col previously described to obtain neutralization anti-
bodies in mice immunized with inactivated flavivirus
particles used as immunogens [28,29]. In our protocol
published earlier, BALB/C mice were injected intraperi-
toneally with 100 μL-aliquot per animal of virus stock
purified to 107 PFU/mL with complete Freund’s adju-
vant. This was repeated at weeks 3, 5 and 7 with incom-
plete Freund’s adjuvant, and animals were bled at week 8.
Considering that the infectivity index (IP:VP ratio) of
flaviviruses varies between 1:100 and 1:1,000 [59], we es-
timated that a 100 μL-dose containing 106 infectious par-
ticles (IP) corresponded to 108 to 109 physical virus
particles (VP). Knowing that the outer glycoprotein shell
of a mature flavivirus particle is formed by 30 rafts of three
homodimers of the viral surface E protein, viz. 180 copies
of E monomer per virion [60], we calculated a range of
values of 1.8 × 1010 to 1.8 × 1011 copies of E monomer per
dose. The protocol used in the present study for immu-
nization with DIII-RIgE-pseudotyped VLPs was based on
the following parameters: (i) The above-mentioned esti-
mation of the number of 108-109 VP and 1.8 × 1010-1.8 ×
1011 copies of E monomer per dose; (ii) our calculation
that 1 μg total Gag protein (full-length Pr55Gag +major
cleavage product Pr41Gag) corresponded to 2 × 109 VLP;
(iii) the average number of 300 copies of DIII-RIgE copies
per VLP (360 molecules of DIII-DENV1-RIgE and 240
molecules of DIII-WNVKun-RIgE per VLP, as detailed
below in the Results section). (iv) The immunization route
in the work presented here took into account ethical con-
siderations: VLP samples mixed with complete or incom-
plete Freund’s adjuvant were injected into animals via the
subcutaneous route, instead of the peritoneal route previ-
ously used [28,29]. Three series of five 11 week-old mice
were injected with 12-15 μg total Gag protein (viz. 2.4 ×
1010 to 3 × 1010 VLPs per dose, accounting for a range of
7 × 1012 to 9 × 1012 DIII copies per dose) with complete
Freund’s adjuvant, in a total volume of 40-50 μL. The
DIII doses administered subcutaneously with VLPs were
therefore 50-fold higher than the dose of E-monomer
protein used in our previous immunization protocol with
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of mice received VLP-DENV1, another received VLP-
WNVKun, and the third series consisted of mice injected
with nonpseudotyped VLPs (VLP-0), to serve as negative
control. Injections were repeated at weeks 3, 5 and 7
with the same doses, along with incomplete Freund’s ad-
juvant, and animals bled at week 8. Sera were probed for
anti-DENV1 and anti-WNVKun antibodies using ELISA,
and for virus neutralizing antibodies using plaque reduc-
tion neutralization test.
Assays for humoral response in mice immunized with VLPs
(i) ELISA. The ELISA protocol utilized here was
similar to that used to determine the binding of patient
antisera to pseudotyped VLPs. (i) Five hundred PFU of
live virus was coated onto well bottoms. (ii) Mouse sera
raised against DIII-pseudotyped VLPs or VLP-0
negative control were used as primary antibodies. (iii)
Anti-mouse IgG-biotin conjugate (Chemicon Inc.) was
used as secondary antibodies.
(ii) Plaque reduction neutralization test (PRNT). The
occurrence of flavivirus neutralizing antibodies in mouse
sera was assayed using PRNT [28,29]. Prior to PRNT, all
sera were inactivated at 56°C for 30 min. Heat-
inactivated sera were diluted in RPMI containing 2% FBS
(virus diluent) at 1:10 ratio, and incubated with 500 PFU
of virus at 37°C for 1 h. The virus-antibody mixtures
were transferred in triplicates onto confluent BHK cell
monolayers, and incubated at 37°C for 1 h. The cell
monolayers were then washed with virus diluent, and
overlaid with overlay medium. Depending on the virus
type, plaques were visualized by staining the monolayer
with 0.5% crystal violet in a 25% formaldehyde solution
at three (WNVKun) or four (DENV1) days post-infection.
Ethics statement
All patients positive for DENV1 infection provided written
informed consent for the use of their sera, which were
used under ethical approval by the Domain Specific Re-
view Boards of Singapore (DSRB, Ref. B/05/013). Animals
used in this study were handled at Eurogentec SA
(Belgium), in compliance with the following association’s
requirements: the Federation of European Laboratory Ani-
mal Science Associations (FELASA), the UK Home Office
Animals Scientific Procedures Act, and the USA National
Institutes of Health Approved Supplier (Animal Welfare
Assurance #A5337-01). FELASA (www.felasa.eu) is a con-
sortium of European Community government animal eth-
ics committees dedicated to the ethical use of research
animals across all EU countries. The immunization work
was performed at Eurogentec SA, and our immunization
protocol approved by the Ethics Committee of the Centre
d'Economie Rurale (CER Groupe, Marloie, Belgium). Ouranimal protocol received the permit number FR10277-
10278-10279.
Results
Incorporation of CD16-RIgE into VLPs produced by
insect cells
This experiment was designed to verify whether in insect
cells the two recombinant proteins, CD16-RIgE and
Pr55GagHIV, would behave as in mammalian cells, co-
localize in the same microdomains of the plasma mem-
brane, and eventually be co-incorporated in budding
VLPs. The cDNA for CD16-RIgE was cloned into the gen-
ome of baculovirus AcMNPV to generate recombinant
AcMNPV-CD16-RIgE (Figure 1). Sf9 cells were infected
with AcMNPV-CD16-RIgE or AcMNPV-Pr55GagHIV
alone, or coinfected with AcMNPV-Pr55GagHIV and
AcMNPV-CD16-RIgE. Cells were harvested at 48 hpi, and
whole cell lysates and extracellular VLPs, isolated as de-
scribed in the Materials and Methods section, were probed
for CD16-RIgE and Pr55GagHIV proteins, using SDS-
PAGE and Western blot analysis. The intracellular anti-
CD16 reacting protein was detected as a major band of
37 kDa in apparent molecular weight (Figure 2A, left
panel), whereas it was visible as a blurred band at 72-75
kDa in VLPs (Figure 2A, right panel). The difference in
the apparent molecular weights suggested that the CD16-
RIgE protein incorporated into VLPs was in a highly
glycosylated form. The fact that VLPs were purified by
two ultracentrifugation steps, velocity ultracentrifugation
through a sucrose cushion, followed by isopycnic ultracen-
trifugation in a sucrose-D2O preformed gradient, and that
DIII-RIgE remained associated with Gag polyprotein
throughout the purification procedure suggested that
retroviral VLPs were pseudotyped with the human glyco-
protein CD16-RIgE.
Sf9 cells coinfected with AcMNPV-Pr55GagHIV and
AcMNPV-CD16-RIgE, and control single AcMNPV-
Pr55GagHIV-infected Sf9 cells harvested at 48 hpi were
processed for electron microscopy (EM). VLPs budding at
the plasma membrane of coinfected cells showed a fuzzy
aspect of their surface (Figure 2B, i), contrasting with the
smooth surface of control, nonpseudotyped VLPs pro-
duced by AcMNPV-Pr55GagHIV-infected cells (Figure 2B,
ii). This result, which confirmed the immunological ana-
lysis of VLPs shown in Figure 2A, implied that CD16-RIgE
and Gag were associated as pseudotyped VLPs, and in-
cited us to use CD16-RIgE as a platform for the insertion
of flaviviral antigens.
Expression of fusion proteins DIII-DENV1-RIgE and
DIII-WNVKun-RIgE in human and insect cells
Our antigenic constructs included the structural domain
DIII of the envelope glycoprotein from two flaviviruses
used as prototypes, DENV serotype 1 (DENV1) and
(i) (ii) 
(B) Electron microscopy    
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Figure 2 Pseudotyping of VLPs with CD16-RIgE protein. (A), Western blot analysis of CD16-RIgE-expressing cells and CD16-RIgE-pseudotyped
VLPs. Left panel: whole cell lysates. Sf9 cells were mock-infected (lane 1), infected with AcMNPV-Pr55GagHIV (lane 2), coinfected with AcMNPV-
Pr55GagHIV and AcMPV-CD16-RIgE at equal MOI each (10 pfu/cell; lane 3), or infected with AcMPV-CD16-RIgE (lane 4). Lysates of cells harvested at
48 hpi were analysed by SDS-PAGE and immunoblotting, using a dual color detection: blots were reacted with anti-Gag rabbit polyclonal
antibody (Ab) and peroxidase-labeled anti-rabbit IgG Ab, followed by mouse monoclonal anti-CD16 Ab and phosphatase-labeled anti-mouse IgG
Ab. The Pr55GagHIV polyprotein precursor shows as a sepia red-colored band at 55 kDa (Pr55Gag), and the chimeric CD16-RIgE protein as a sharp
purple blue band at 37 kDa. Lane m, molecular weight markers. Right panel: extracellular VLPs. VLPs isolated from the culture medium of cells
expressing Pr55GagHIV alone (lane 1), coexpressing Pr55GagHIV and CD16-RIgE (lane 2), and the corresponding samples from CD16-RIgE-expressing
cells (no VLP control; lane 3) were analysed by SDS-PAGE and immunoblotting, as above. The Pr55Gag cleavage products (Pr47, Pr41 and CAp24
[9-15]) are indicated by dotted lines, and the chimeric CD16-RIgE protein, migrating as a blurred band at 72-75 kDa, by a blue arrow. (B), Electron
microscopy (EM) of ultrathin sections of VLP-producing cells. (i), Double infection. Sf9 cells were coinfected with two recombinant baculoviruses
AcMNPV-Pr55GagHIV and AcMNPV-CD16-RIgE, and processed for EM at 48 hpi. (ii, inset), Control single infection. Sf9 cells infected with
AcMNPV-Pr55GagHIV alone produced nonpseudotyped VLP. Note the difference between the fuzzy (i) and smooth (ii) envelopes of VLPs.
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choice of this domain was the finding that DIII was cap-
able of inducing a robust antiviral response and virus-
specific neutralizing antibodies [26-36,56]. The CD16
ectodomain was deleted from the pcDNA3.1/CD16-RIgEvector, and replaced by the coding sequences of His6-
tagged DIII-DENV1 or DIII-WNVKun (refer to Figure 1).
When expressed in human cell line HEK293 using plas-
mid vector pcDNA3.1, the fusion constructs DIII-DENV1-
RIgE and DIII-WNVKun-RIgE were found to react with
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http://www.virologyj.com/content/10/1/129anti-His6 tag antibody (immunolabelled with green Alexa
Fluor 488-conjugated secondary antibody) in immuno-
fluorescence (IF) confocal microscopy of nonperme-
abilized cells, and localized at the plasma membrane,
stained with red-fluorescent WGA (Figure 3). This indi-
cated that DIII-DENV1-RIgE and DIII-WNVKun-RIgE
were addressed to the plasma membrane of HEK293 cells,
like parental CD16-RIgE, and that the two DIII domains
were exposed at the cell surface, as ectodomains of DIII-
RIgE fusion proteins.
Baculovirus vectors were then constructed to express
each chimeric protein, DIII-DENV1-RIgE or DIII-WNVKun-
RIgE alone, or in coexpression with recombinant
Pr55GagHIV. The two clones showed a similarly high
level of expression of recombinant proteins in Sf9 cells
(Figure 4a). They migrated with an apparent molecular
mass of 22-23 kDa, a value which was consistent with
their amino acid sequences: DIII-DENV1-RIgE comprised
of 194 residues including the His6 tag (6 residues), DIII
domain (123 residues), 2 leftover residues from the deleted
CD16 ectodomain, and the transmembrane and cytoplas-
mic domains of FcεRIγ (63 residues). In IF confocal mi-
croscopy, the N-terminal His6 tag of DIII-DENV
1-RIgE
and DIII-WNVKun-RIgE chimeric proteins was found to
react with anti-His6 tag antibody at the cell surface of
nonpermeabilized Sf9 cells (Figure 4b, c), indicating that
the DIII domain was exposed at the surface of Sf9 cells, as
in HEK293 cells.
Coexpression with Pr55GagHIV, as detailed below, did
not significantly change the confocal IF pattern of
membrane-display of DIII-DENV1-RIgE or DIII-WNVKun-
RIgE (Figure 4d). After cell permeabilization, to give anti-Figure 3 Confocal immunofluorescence (IF) microscopy of human cel
transfected with pcDNA3.1 plasmid expressing DIII-DENV1-RIgE or DIII-WNV
posttransfection without cell permeabilization. Plasma membrane was stain
33342, and DIII-RIgE fusion proteins immunodetected with monoclonal ant
antibody. (A), Control cells transfected with empty pcDNA3.1 plasmid. (B), C
transfected with pcDNA3.1-DIII-WNVKun-RIgE plasmid. Panels (a) show view
plane reconstructed from Z-stack images. Note that DIII-DENV1-RIgE and DI
nonpermeabilized cells, and that they localized in membrane microdomainGag antibody access to intracellular Gag polyprotein,
double IF staining showed the co-localisation of
Pr55GagHIV and DIII-DENV1-RIgE or DIII-WNVKun-RIgE
at the plasma membrane of co-expressing Sf9 cells
(Figure 5).Incorporation of the DIII-RIgE fusion proteins into VLPs
In order to test the capacity of each fusion construct to be
incorporated into VLPs, Sf9 cells were coinfected pairwise
with two baculoviruses, (i) AcMNPV-Pr55GagHIV, which
provided the common structural platform, and (ii)
AcMNPV-DIII-DENV1-RIgE or AcMNPV-DIII-WNVKun-
RIgE, which provided the surface protein specific of each
VLP pseudotype. Extracellular VLPs were first isolated
from the culture medium at 48 hpi, using ultracentrifuga-
tion through a 20% sucrose cushion [61]. The DIII signal
was found in the VLP pellet, associated with the Gag
signal (Figure 6A). VLP pellet was then resuspended in
PBS and further purified by isopycnic ultracentrifugation
in preformed sucrose-D2O gradient. The Gag poly-
protein and the His6-tagged DIII-DENV
1-RIgE and
DIII-WNVKun-RIgE cosedimented in gradient fractions
corresponding to the apparent density of VLPs (ρ =
1.15-1.20; Figure 6B, C). In the absence of expression of
Pr55GagHIV, the His6-tag signal was found in the gradi-
ent top fractions containing soluble proteins (not
shown). These results indicated that, when coexpressed
with Pr55GagHIV, DIII-DENV1-RIgE and DIII-WNVKun-
RIgE fusion proteins were bona fide components of the
Gag VLPs, and were not carried over during the VLP
isolation process.ls expressing DIII-RIgE fusion proteins. HEK293 cells were
Kun-RIgE, and analysed by fluorescence imaging at 48 h
ed with red-fluorescent WGA, nuclei with blue-fluorescent Hoechst
i-His6 tag antibody and Alexa Fluor
W 488-labeled goat anti-mouse IgG
ells transfected with pcDNA3.1-DIII-DENV1-RIgE plasmid. (C), Cells
s from the apical pole; panels (b) show the corresponding sagittal cell
II-WNVKun-RIgE proteins were accessible at the surface of
s different from WGA-reacting regions.
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Figure 4 Expression and localization of DIII-RIgE fusion proteins in insect cells. (a), Western blot analysis. Sf9 were mock-infected (control
lane 1), or infected with parental baculovirus vector (control lane 2), recombinant AcMNPV expressing CD16-RIgE (control lane 3), DIII-DENV1-RIgE
(lane 4), or DIII-WNVKun-RIgE (lane 5). Cells were harvested at 48 hpi and cell lysates analysed by SDS-PAGE and Western blotting. The 22-23 kDa
bands of the envelope DIII-RIgE fusion proteins were detected using monoclonal anti-His6 tag antibody and complementary phosphatase-labeled
antibody. (b-d), Confocal IF microscopy. Sf9 cells were infected with AcMNPV expressing DIII-DENV1-RIgE (b), DIII-WNVKun-RIgE (c), or coinfected
with AcMNPV-DIII-WNVKun-RIgE and AcMNPV-Pr55GagHIV (d). Cells were harvested at 48 hpi and reacted with monoclonal anti-His6 tag antibody
and Alexa Fluor® 488-labeled goat anti-mouse IgG antibody, without cell permeabilization. Nuclei were stained with blue-fluorescent DAPI. Note
that the fluorescent signal of the anti-His6 tag localized at the cell surface and outlined the cell contour.
Figure 5 Colocalization of Pr55GagHIV and DIII-RIgE in membrane-permeabilized insect cells. Sf9 cells were coinfected with AcMNPV-
Pr55GagHIV and (A) AcMNPV-DIII-DENV1-RIgE, or (B) AcMNPV-DIII-WNVKun-RIgE, and harvested at 48 hpi. Cells were permeabilized and reacted with
monoclonal anti-His6 tag antibody and Alexa Fluor
W 488-labeled goat anti-mouse IgG antibody, and rabbit polyclonal anti-Gag antibody and
Alexa FluorW 594-labeled anti-rabbit IgG antibody. (a), phase contrast; (b), DAPI staining, (c), Alexa FluorW 488 channel; (d), Alexa FluorW 594
channel; (e), merged fluorescence images. All images were visualized at 100X magnification.
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Figure 6 Protein analysis of DIII-pseudotyped VLPs. (A-C), VLPs were purified from the culture medium of Sf9 cells infected with AcMNPV-
Pr55GagHIV or coinfected with AcMNPV-Pr55GagHIV and AcMNPV-DIII-DENV1-RIgE or AcMNPV-DIII-WNVKun-RIgE. (A), VLPs from Pr55GagHIV-
expressing cells (lane 1), from Pr55GagHIV + DIII-DENV1-RIgE coexpressing cells (lane 2), or from Pr55GagHIV + DIII-WNVKun-RIgE coexpressing cells
(lane 3) were isolated by centrifugation through a sucrose cushion. VLP samples were analyzed by SDS-PAGE and Western blotting. Dual color
was obtained by reaction of the blot with anti-Pr55Gag rabbit antibody and peroxidase-labeled anti-rabbit IgG antibody, which revealed the
Pr55GagHIV polyprotein and its major cleavage products (Pr47GagHIV and Pr41GagHIV) in sepia red; this was followed by a second reaction with
monoclonal anti-His6 tag antibody and phosphatase-labeled anti-mouse IgG, which revealed the DIII-RIgE fusion proteins in purple blue. Lane m,
molecular weight markers. (B, C), VLP pellets in (A) from cells coexpressing DIII-RIgE and Pr55GagHIV were further purified by density
ultracentrifugation in sucrose-D2O isopycnic gradient, and analyzed by SDS-PAGE and Western blotting, as above. (B), DIII-DENV
1-RIgE; (C),
DIII-WNVKun-RIgE. (D), VLPs were isolated from cells coexpressing DIII-WNVKun-RIgE and (lane 1) human virus Pr55GagHIV, (lane 2) simian virus
Pr57GagSIV, (lane 3) chimeric murine-human virus Pr72GagMLV-HIV, or (lane 4) murine virus Pr65GagMLV. VLPs were analyzed by SDS-PAGE and
Western blotting. Blots were reacted with rabbit anti-Gag antibodies and mouse anti-His6 tag monoclonal antibody, followed by peroxidase-
labeled anti-rabbit IgG and anti-mouse IgG antibodies, then revealed by chemiluminescence substrate. Due to differences in the intensity of
immunoreactivity of Gag proteins with polyclonal antibodies, compared to that of DIII-WNVKun-RIgE with monoclonal antibody, the blot was
subjected to different exposure times: the luminogram showing the DIII-WNVKun-RIgE protein (lower panel) corresponds to a longer exposure.
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incorporation of DIII-RIgE
It has been shown that incorporation of envelope glyco-
protein SUgp120 of HIV-1 into the retroviral particle re-
quires specific interactions between the cytoplasmic tail of
TMgp41 with the N-terminal region of the matrix domain
(MA) of Pr55GagHIV [9,40,62]. Our next experiment was
designed to determine the influence of the Gag polypro-
tein species on the pseudotyping of VLPs by our chimeric
DIII-RIgE constructs. To this aim, we used AcMNPV-
Pr57GagSIV, AcMNPV-Pr65GagMLV and AcMNPV-
Pr72GagMLV-HIV as alternatives to Pr55GagHIV to constitute
the inner backbone of VLPs. AcMNPV-Pr57GagSIV and
AcMNPV-Pr65GagMLV expressed the N-myristoylated,
full-length Gag polyproteins of SIVmac251 (Pr57Gag) and
MLV (Pr65Gag), respectively. AcMNPV-Pr72GagMLV-HIV
expressed a chimeric Gag polyprotein consisting of the
N-myristoylated MA-CA domains of MLV fused to the
SP1-NC-p6 domains of HIV-1 Gag [44]. The incorpora-
tion of DIII-WNVKun-RIgE was found to occur in VLPSIV,
VLPMLV and VLPMLV-HIV (Figure 6D), and similar results
were obtained with DIII-DENV1-RIgE (not shown). This
suggested that incorporation of DIII-RIgE into VLPs was
not restricted to one single Gag species, and that the use
of VLPs made of other Gag polyprotein species could be
envisaged.
Immunological characterization of VLP-DIII pseudotypes
(i) Quantitative analysis of DIII incorporation by
VLPs. The DIII-RIgE content of VLPs was quantitatively
determined by SDS-PAGE analysis and gel scanning.
VLPs were coelectrophoresed in SDS-polyacrylamide
gels with a range of BSA samples of defined
concentrations. Gels were stained with Coomassie blue.
Gag and DIII protein bands were scanned and
quantitated by densitometric analysis, using ImageJ
program (NIH) and a quantification method cited in
[63] and detailed in the website lukemiller.org. Both
bands of Pr55GagHIV precursor and its major cleavage
product Pr41Gag were taken into account in our
calculation of Gag protein content. We found a protein
ratio ranging between 15 and 30 ng of DIII-RIgE per μg
total Gag protein (i.e. per 2 × 109 VLPs), and calculated
a mean number of 360 ± 30 copies (m ± SEM; n = 4) per
VLP for DIII-DENV1-RIgE, and 240 ± 25 copies (m ±
SEM; n = 4) per VLP for DIII-WNVKun-RIgE. Of note,
the flavivirus envelope is composed of 30 rafts
containing 3 homodimeric E glycoproteins each, viz.
180 copies of E monomer per particle [60,64]. The
difference in the VLP envelope incorporation efficiency
between DIII-DENV1-RIgE and DIII-WNVKun-RIgE,
could not be explained by a difference in the level of
cellular expression of DIII-WNVKun-RIgE protein,compared to DIII-DENV1-RIgE (refer to Figure 4A),
but was likely due to the intrinsic property of each
individual DIII construct. Whatever the mechanism,
we used the average number of 300 copies of DIII-
RIgE copies per VLP to calculate the proper VLP
doses to be injected in mice immunization protocols,
as detailed in the Materials and Methods section.
(ii) Immunoelectron microscopy (immuno-EM).
Accessibility of DIII antigens incorporated in the VLP
envelope was first analyzed qualitatively by
immunoelectron microscopy, using anti-His6 tag
antibody to detect the N-terminal His6 tag of DIII-
DENV1-RIgE and DIII-WNVKun-RIgE. The samples
consisted of VLPs obtained by ultracentrifugation
through sucrose cushion, which were partially
purified from the particles of the baculoviral vector.
This partial purification through the omission of
isopycnic sucrose-D2O ultracentrifugation allowed us
to assess the specificity of labeling of the different
particles. As shown in Figure 7, immunogold labeling
was found specifically to associate with VLPs, and not
with baculovirions. This demonstrated that DIII-
DENV1-RIgE and DIII-WNVKun-RIgE were exposed
at the surface of Gag VLPs, and immunologically
reactive. This further supported our findings in the
earlier ultracentrifugation experiments (refer to
Figure 6), and provided conclusive visual evidence
that DIII-DENV1-RIgE and DIII-WNVKun-RIgE fusion
proteins were bona fide components of Gag VLPs. Of
note, costaining of VLPs with anti-Gag antibodies was
not possible as the Gag protein is not accessible to
antibodies in membrane-enveloped VLPs, whereas the
ectodomain of membrane-inserted proteins, such as
DIII-RIgE, was exposed to the exterior and fully
accessible.
(iii) ELISA. In order to confirm the accessibility and
specific immunoreactivity of VLP-incorporated DIII-
DENV1-RIgE and DIII-WNVKun-RIgE, VLP fractions
were analyzed by ELISA, using patient sera positive
for DENV1, and monoclonal and polyclonal antibodies
against WNVKun DIII. The reactivity of VLP-DENV1
with specific anti-DENV1 antibodies from two
different patient sera was significant, compared to the
background signals obtained with control VLP devoid
of DIII (VLP-0; Figure 8A). Likewise, VLP-WNVKun
reacted with anti-WNV DIII monoclonal and
polyclonal antibodies at significant levels (Figure 8B).
The immunoreactivity of DIII-DENV1-RIgE antigen
with anti-DENV1 antibodies was found to be VLP
dose-dependent (Figure 8C). These results confirmed
the structural and antigenic conformation of the DIII
antigens at the surface of VLPs, as suggested by the
data of IF and immuno-EM using anti-His6 tag
antibody.
Figure 7 Immuno-EM analysis of DIII-pseudotyped VLPs. Extracellular VLPs released from Sf9 cells co-expressing Pr55GagHIV and DIII-RIgE
fusion protein, were isolated by ultracentrifugation through sucrose cushion. Aliquots of VLP samples were adsorbed on EM grids and reacted
with monoclonal anti-His6 tag antibody, and secondary 10-nm colloidal gold-labeled anti-mouse IgG. (a), Control VLPs devoid of DIII (VLP-0);
(b-d), VLP-displayed DIII-DENV1-RIgE; (e, f), VLP-displayed DIII-WNVKun-RIgE. Specimens were negatively stained with sodium phosphotungstate.
BV, baculovirus vector. Note that all visible gold grains are found to be associated with membrane-enveloped VLPs of 120-130 nm in diameter
[12]. Scale bar represents 100 nm in (a-c) and (e-f), and 20 nm in (d).
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Figure 8 Immunoreactivity of VLP-displayed DIII. (A), Aliquots of
control VLPs devoid of DIII (VLP-0) or VLPs pseudotyped with DIII-
DENV1-RIgE (VLP-DENV1) were coated on plates and probed by
ELISA for reactivity towards two different samples of patient sera
positive for DENV1 infection. (B), Aliquots of control VLP-0 or VLPs
pseudotyped with DIII-WNVKun-RIgE (VLP-WNVKun) were tested by
ELISA for reactivity towards two different types of anti-WNV DIII
antibodies, mouse monoclonal 3.67G and rabbit polyclonal (PC)
anti-WNV DIII antibodies. (C), Dose-dependent reactivity of
VLP-DENV1 with DENV1-specific patient antibodies. Data presented
are mean ± SEM, n = 4; (*), significantly different at p < 0.05 level.
Chua et al. Virology Journal 2013, 10:129 Page 13 of 18
http://www.virologyj.com/content/10/1/129Immunogenicity of VLP-displayed flaviviral DIII in vivo
Three groups of five 11-week old mice were immu-
nized with VLP-displayed (i) DIII-DENV1-RIgE, (ii)
DIII-WNVKun-RIgE, and (iii) VLP-0, the negative con-
trol consisting of nonpseudotyped VLPs.
(i) Induction of antibodies against live flaviviruses.
Sera were probed for the presence of antibodies against
flavivirus, using ELISA plates coated with live WNVKun
and DENV1 virions. In the VLP-DENV1-immunized
group, sera from 2 out of 5 mice were positive forDENV1 virus at all dilutions tested (1:10, 1:50, 1;100,
and 1:200), and reacted in a dose-dependent manner
(Additional file 1: Figure S1). Similarly, sera from 2 out
of 5 mice were positive for WNVKun virus and reacted
in a dose-dependent manner in the VLP-WNVKun-
immunized group (Additional file 2: Figure S2). Thus,
in mice which responded to the flavivirus DIII antigen
at detectable levels, the ELISA showed a moderate
antibody response towards the corresponding live virus
particles.
(ii) Induction of flavivirus neutralizing antibodies. The
antiviral neutralization response was evaluated using
the plaque reduction neutralization test (PRNT). PRNT
is the method of choice for evaluating the potency and
efficacy of anti-flavivirus vaccines, as it determines the
flavivirus neutralization activity (NA) of a serum, i.e.
the capacity of circulating antibodies to block virus
infection. PRNT showed that sera from 3 out of 5 mice
injected with VLP-DENV1 contained neutralizing
antibodies against DENV1, with NA titers ranging from
20 to 30% at dilution 1:10 (Figure 9A). For mice
immunized with VLP-WNVKun, 3 sera out of 5 had
neutralizing antibodies against WNVKun virus, with NA
titers ranging from 25 to 50% at dilution 1:10
(Figure 9B). Although relatively modest, this
neutralization response against DENV1 and WNVKun
viruses was significant. No NA against either virus was
detected in sera of mice immunized with VLP-0: the
PRNT values obtained were within the limits of the
background values (-10 to +10% NA) at all dilutions
tested (not shown).
(iii) Absence of correlation between DENV1 and anti-
WNVKun antibody levels and virus neutralization
activity. Comparison of the ELISA and PRNT data
showed that for DENV1, mice #4 and #5 developed the
highest levels of total anti-DIII-DENV1 antibodies
(detected by ELISA; refer to Additional file 1: Figure
S1), whereas sera of mice #2, #3 and #4 were the
highest in NA titer (detected by PRNT; refer to
Figure 9A). Only one animal, mouse #4, had both high
levels of total anti-DIII-DENV1 antibodies and
significant levels of DENV1 virus neutralizing
antibodies. In the case of WNVKun, mice #1 and #4
developed the highest levels of total anti-DIII-WNVKun
antibodies, whereas sera of mice #2, #3 and #5 showed
the highest NA against WNVKun virus (compare
Figure 9B and Additional file 2: Figure S2). There was
an apparent discrepancy between ELISA and PRNT:
PRNT detected neutralizing antibodies in some of the
immunized animals whereas their total antiviral
antibodies were at background levels in ELISA. This
was likely due to technical differences in the assays: in
ELISA, live WNVKun and DENV1 virions were
immobilized on a solid support, whereas in PRNT, they
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Figure 9 Induction of flavivirus neutralization antibodies by VLP-displayed DIII antigen. The occurrence of anti-DENV1 or anti-WNVKun
neutralizing antibodies in sera of mice immunized with VLPs displaying the corresponding DIII at their surface was determined using plaque
reduction neutralization test (PRNT). (A), Sera from mice immunized with VLP-DENV1 were diluted to 1:10 and tested against live DENV1 virions.
(B), Sera from mice immunized with VLP-WNVKun (1:10 dilution) were tested against live WNVKun virions. Neutralization activity of sera was
expressed as the percentage of virus neutralization, based on plaque determinations (average of three determinations, m ± SD).
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interaction with antibodies. This allowed neutralizing
antibodies to bind to cryptic epitopes while the virions
“breathe” in solution during incubation, as recently
suggested [65]. Such structural dynamics will not be
possible in immobilized virions. Whatever the
mechanism, the absence of correlation between the
total levels of antibodies induced by VLP-DIII in
immunized animals and their capacity to neutralize the
live viruses implied that only a certain population of
antibodies were neutralizing.
(iv) Anti-Gag response. The antibodies induced against
the core components of the VLP carriers, were
evaluated by ELISA, using recombinant Pr55GagHIV
polyprotein expressed in AcMNPV-Pr55GagHIV-
infected Sf9 cells, with mock-infected Sf9 cell lysate as
negative control. We observed significant levels of anti-
Gag response in some of the immunized mice
(Additional file 3: Figure S3). However, there was no
correlation between the level of the anti-Gag response
and that of the anti-DIII response whatever the
immunogen used, VLP-0 versus VLP-DIII-DENV1 or
VLP-DIII-WNVKun (compare Additional file 1: Figure S1,Additional file 2: Figure S2 and Additional file 3: S3).
Likewise, there was no correlation between the level of
anti-Gag antibodies and the level of DENV1 or WNVKun
neutralizing antibodies (compare Figure 9 with
Additional file 3: Figure S3). This indicated that the anti-
flaviviral DIII response was independent of the response
towards the VLP carriers, and was more complex than
the simple reflection of the whole responsiveness of
immunized animals.
Discussion
In the present study, DENV serotype 1 was our Dengue
virus prototype, and the extensively studied Kunjin strain
was selected as our WNV prototype. WNV Kunjin, which
was isolated in Australia, belongs to lineage 1, and strains
in lineage 1 are generally more virulent and neuro-
invasive. The choice of the strategy of VLP-display of the
structural DIII domain of flavivirus envelope glycoprotein
for potential vaccine antigen was based on the following
considerations. The structure of DIII resembles that of the
constant domain of immunoglobulins, and its flexible
loops exposed on the exterior of the mature virions are
the major determinants of the global immunogenicity of
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munogenic. More importantly, it carries neutralizing epi-
tope(s) of the envelope glycoprotein, and thus is capable
of inducing a robust immune response and neutralizing
antibodies [5,26-37,56]. Antibodies binding to epitopes on
DIII have been detected in sera of patients with DENV
and WNV infections [68-72]. The presentation of solely
the DIII domain, instead of the whole envelope glycopro-
tein, has the advantage of focusing the immune response
on the neutralizing epitopes on DIII. Furthermore, this
strategy excludes the DII domain, which harbours
immunodominant, but non-neutralizing epitopes. Con-
sidering the over-representation of non-neutralizing,
cross-reactive, domain II-binding antibodies in WNV-
infected patients, DIII-based vaccines reduce the poten-
tial risk of antibody-dependent enhancement of infection
in vaccinated individuals if infected with a heterologous
flavivirus [73].
The expression of DIII proteins in insect cells was jus-
tified by the fact that the flavivirus life cycle involves a
mosquito vector as an intermediate host. Thus, flaviviral
proteins will follow a biosynthetic pathway and posttrans-
lational modifications in Sf9 cells similar to that which
naturally occur in the insect vector. VLPs, as other par-
ticulate structures, are known to possess adjuvant proper-
ties [5,23], and this represents a significant advantage for
vaccination strategies. The choice of recombinant
Pr55GagHIV as our proof-of-concept was determined by
the high productivity of VLPs when recombinant HIV-1
gag gene was expressed in baculovirus-infected cells, com-
pared to other systems [10]. We have previously shown
that in AcMNPV-Pr55GagHIV-infected Sf9 cells, 2 × 108 to
5 × 108 Pr55GagHIV molecules/cell were produced and re-
leased into the extracellular medium at 48 hpi. This
corresponded to 5 × 104 to 1 × 105 VLPs per cell, if one
considers that 5 × 103 Gag molecules are required to form
one VLP [51,52]. Interestingly, we found that pseudo-
typing of VLPs by DIII-RIgE was not restricted to the
lentiviral Pr55GagHIV backbone, but was also observed
with distantly related retroviral Gag polyproteins, such as
MLV Gag polyprotein Pr67GagMLV. This implied that our
VLP-display platform could be extended to MLV-based
VLPs, which has been clinically approved as vector for
gene therapy by health regulatory agencies such as FDA.
We found that when the DIII domains of the envelope
glycoproteins of DENV1 and WNVKun were fused to the
N-terminal signal peptide (SP) of human CD16, and to
the transmembrane and cytoplasmic domains of the
gamma chain of the human high affinity receptor for IgE
(RIgE) at their C-termini, the resulting fusion constructs
DIII-DENV1-RIgE and DIII-WNVKun-RIgE were ad-
dressed to the plasma membrane of human and insect
cells. None of the fusion protein seemed to be glycosylated:
the DIII domain did not carry any canonical glycosylationsite, and DIII-DENV1-RIgE and DIII-WNVKun-RIgE mi-
grated as sharp bands in SDS-PAGE, with apparent
molecular weights consistent with their amino acid com-
positions and theoretical molecular weight values.
When DIII-DENV1-RIgE and DIII-WNVKun-RIgE were
coexpressed with Pr55GagHIV in insect cells, they were ef-
ficiently incorporated into VLPs, and released into the
extracellular medium as VLP-displayed DIII-RIgE mole-
cules. Immunological analyses showed that the DIII do-
main of the two chimeric constructs were accessible at the
surface of the VLPs. In addition, the ectodomain of DIII-
DENV1-RIgE was immunologically reactive against spe-
cific patient antibodies. This demonstrated the functional-
ity of using the VLPs to present structural domains of the
flavivirus envelope glycoprotein as a substitute to virus-
based vaccines.
The results of mice immunization showed that VLPs
pseudotyped with our DIII-RIgE construct represented a
promising platform for flavivirus vaccines, since a neu-
tralization response against DENV and WNV was induced
in a significant number of mice (60%). In one case for each
vaccine antigen prototype, the NA titer reached 50% at
1:10 serum dilution, a value which fulfilled the WHO cri-
terion for sera to be considered as neutralizing (http://
whqlibdoc.who.int/hq/2007/who_ivb_07.07_eng.pdf). Our
previous immunization regimen, which used bacterially
expressed DIII and GpC adjuvant administered intraperi-
toneally to mice, resulted in 80-90% virus neutralization
effect at 1:128 to 1:16 serum dilutions [29]. However, this
neutralization titer was obtained with 100 μg recombinant
DIII protein per vaccine dose, i.e. a 250- to 500-fold higher
amount compared to our VLP-displayed DIII-RIgE.
The unexpected absence of correlation between anti-
DENV1 and anti-WNVKun antibody levels in our ELISA
and PRNT data might be attributed to the suboptimal
antibody response induced by our prototype pseudotyped
VLP vaccines. Optimisation of our pseudotyping process
to further increase the copy number of DIII-IgE per VLP,
and our immunization protocol (e.g. immunogen dosage,
number of boosts, etc.) has been planned for as part of
our future work to fulfill the WHO criterion for neutraliz-
ing sera in all immunized animals. However, the fact that
the injection of VLPs carrying a limited domain of the fla-
vivirus envelope glycoprotein was sufficient to induce neu-
tralizing antibodies in animals confirmed previous
observations, made by our laboratory and others, that DIII
carried a major neutralizing epitope (reviewed in [74]).
Neutralization of flaviviruses by polyclonal antibodies has
been shown to result from a complex interplay between
several viral components and host factors [74]. More re-
cently, a high-resolution crystallographic analysis of
DENV DIII in complex with a mouse monoclonal anti-
body capable of neutralizing all four DENV serotypes has
dissected the molecular determinants of inter-DENV
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with the DIII-RIgE of DENV serotypes 2, 3 and 4 have also
been planned for, to allow for comparison of cross-
neutralization activities between the sera raised through
immunization with each DIII-RIgE and different DENV
serotypes.
In conclusion, our data showcased, to the best of our
knowledge, the innovative use of pseudotyped Gag VLPs
as a vaccine vector for the display of flaviviral antigens.
Although our results were relatively modest for our first
two prototypes, DENV1 and WNVKun neutralizing anti-
bodies were indeed induced. With further optimization in
our future works, we are confident that our VLP-displayed
CD16-RIgE-based platform will be developed into a versa-
tile vaccine vector against different flaviviruses and other
viral pathogens.
Additional files
Additional file 1: Figure S1. Induction of antibodies against DENV1
virions in mice immunized with VLP-DENV1 versus control, nonpseudotyped
VLP-0. Serial dilutions of each mouse serum were tested against DENV1
virions adsorbed on ELISA wells. Data shown are the average of three
determinations (m ± SEM). The different symbols refer to sera from
individual animals.
Additional file 2: Figure S2. Induction of antibodies against WNVKun
virions in mice immunized with VLP-WNVKun, versus control,
nonpseudotyped VLP-0. Serial dilutions of each mouse serum were
tested against WNVKun virions adsorbed on ELISA wells. Data shown are
the average of three determinations (m ± SEM). The different symbols
refer to sera from individual animals.
Additional file 3: Figure S3. Antibody response against the VLP core
component. Aliquots of lysates from mock-infected or AcMNPV-Pr55Gag
HIV-infected Sf9 cells containing recombinant Pr55Gag polyprotein, were
coated on ELISA wells. Wells were reacted with sera (1:10 dilution) of
mice immunized with control, nonpseudotyped VLP-0 (light grey bars),
VLP-DENV1 (hatched bars), or VLP-WNVKun (black bars). Data shown are
the average of three determinations (m ± SEM), after subtraction of the
background value given by mock-infected Sf9 cell lysates.
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